Table 3. Effects of Gal-3 expression on the cumulative survival of NT cases stratified by age, stage, (INPC) Shimada and histological categorization, MYCN status (no GN included because it is benign by definition).

	Gal-3+			Gal-3−			P
	n	Deaths	Survival, %	n	Deaths	Survival, %
Age (months)
<15	6	0	100.0	33	5	84.8	0.3
⩾15	18	4	77.8	66	45	29.6	0.001
aTotal	24			99
Stage
1-2-4 s	10	0	100.0	37	4	89.2	0.29
3-4	14	4	71.4	62	46	22.6	0.002
aTotal	24			99
(INPC) Shimada
Favorable	20	2	90.0	51	9	81.7	0.35
Unfavorable	4	2	50.0	48	41	13.2	0.19
aTotal	24			99
MYCN
Nonamplified	21	2	90.5	68	20	69.4	0.057
Amplified	3	2	33.3	28	27	3.6	0.11
aTotal	24			96
(INPC) Tumor histology
NB	12	2	83.3	92	47	47.7	0.03
GNB	12	2	83.3	7	3	57.1	0.19
aTotal	24			99

Statistically significant values are in bold

^aGN is not included because it is benign by definition